NCT01046604 - Pilot Study of Lovaza (Omega 3 Fatty Acids) to Improve Cardiac Antioxidant/Anti-inflammatory Profile Before Cardiac Surgery | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

October 31, 2013

Study Completion Date

December 31, 2013

Conditions

Mitral Valve RegurgitationLeft Atrium Dilatation and HypertrophyMitochondrial Dysfunction in the HeartCardiomyocyte ApoptosisCardiac Inflammation

Interventions

DRUG

Lovaza group

Patients who are scheduled for mitral valve repair surgery at least 3 weeks removed from the initial consult will be recruited to take 4 capsules of Lovaza (omega 3 fatty acids) daily, for 3 weeks prior to their surgery.

Trial Locations (1)

27834

Brody School of Medicine, Greenville